These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35890181)

  • 21. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
    Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
    Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC).
    Cordani N; Lisini D; Coccè V; Paglia G; Meanti R; Cerrito MG; Tettamanti P; Bonaffini L; Paino F; Alessandri G; Marcianti A; Giannì A; Villa C; Mauri M; Mologni L; Torsello A; Pessina A; Cazzaniga ME
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
    Chang Q; Geng R; Wang S; Qu D; Kong X
    Drug Deliv; 2016 Nov; 23(9):3629-3638. PubMed ID: 27749106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer.
    Qin T; Xu X; Zhang Z; Li J; You X; Guo H; Sun H; Liu M; Dai Z; Zhu H
    Nanotechnology; 2020 Sep; 31(36):365101. PubMed ID: 32434167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coaxial electrostatic spray-based preparation of localization missile liposomes on a microfluidic chip for targeted treatment of triple-negative breast cancer.
    Wang Q; Xu W; Li Q; He C; Liu Y; Liu J; Wang R; Wu J; Xiang D; Chen C
    Int J Pharm; 2023 Aug; 643():123220. PubMed ID: 37437856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The theranostic efficiency of tumor-specific, pH-responsive, peptide-modified, liposome-containing paclitaxel and superparamagnetic iron oxide nanoparticles.
    Zheng XC; Ren W; Zhang S; Zhong T; Duan XC; Yin YF; Xu MQ; Hao YL; Li ZT; Li H; Liu M; Li ZY; Zhang X
    Int J Nanomedicine; 2018; 13():1495-1504. PubMed ID: 29559778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs.
    Tang H; Xie Y; Zhu M; Jia J; Liu R; Shen Y; Zheng Y; Guo X; Miao D; Pei J
    Int J Nanomedicine; 2022; 17():3013-3041. PubMed ID: 35836838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of Curcumin and Paclitaxel Liposomes Exhibits Enhanced Cytotoxicity Towards A549/A549-T Cells and Unaltered Pharmacokinetics.
    Feng X; Pi C; Fu S; Yang H; Zheng X; Hou Y; Wang Y; Zhang X; Zhao L; Wei Y
    J Biomed Nanotechnol; 2020 Aug; 16(8):1304-1313. PubMed ID: 33397559
    [No Abstract]   [Full Text] [Related]  

  • 29. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
    Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
    Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
    Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
    ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The anticancer efficacy of paclitaxel liposomes modified with low-toxicity hydrophobic cell-penetrating peptides in breast cancer: an
    Zhang Q; Wang J; Zhang H; Liu D; Ming L; Liu L; Dong Y; Jian B; Cai D
    RSC Adv; 2018 Jul; 8(43):24084-24093. PubMed ID: 35539172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
    He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
    Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
    Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J
    Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
    Shi C; Cao H; He W; Gao F; Liu Y; Yin L
    Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model.
    Franco MS; Roque MC; de Barros ALB; de Oliveira Silva J; Cassali GD; Oliveira MC
    Biomed Pharmacother; 2019 Jan; 109():1728-1739. PubMed ID: 30551427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
    Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
    Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations.
    Ye J; Li R; Yang Y; Dong W; Wang Y; Wang H; Sun T; Li L; Shen Q; Qin C; Xu X; Liao H; Jin Y; Xia X; Liu Y
    J Nanobiotechnology; 2021 Jul; 19(1):199. PubMed ID: 34225762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
    Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
    J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities.
    Venugopal V; Krishnan S; Palanimuthu VR; Sankarankutty S; Kalaimani JK; Karupiah S; Kit NS; Hock TT
    PLoS One; 2018; 13(11):e0206109. PubMed ID: 30408068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.